Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)A CETUXIMAB (GENETICAL RECOMBINATION) (100 MG/1 VIAL) 660 VIALS B AFLIBERCEPT (GENETICAL RECOMBINATION) (40 MG/ML/1 VIAL) 940 VIALS C TOCILIZUMAB (GENETICAL RECOMBINATION) (400 MG/1 VIAL) 301 VIALS D BEVACIZUMAB (GENETICAL RECOMBINATION) (100 MG/4 ML/1 VIAL) 878 VIALS E BEVACIZUMAB (GENETICAL REC...

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Jan 23, 2017
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Hokkaido
Classification
0004 Medical & Pharmaceutical Products
Summay of notice 5 Summary
(1) Official in charge ofdisbursement of the procuring
entity : Akitoshi Yoshida,President, Asahikawa Medical
University
(2) Classification of the products
to be procured : 4
(3) Nature and quantity of theproducts to be purchased :
A Cetuximab (GeneticalRecombination) (100 mg/1 vial) 660
vials
B Aflibercept (GeneticalRecombination) (40 mg/ml/1 vial)
940 vials
C Tocilizumab (GeneticalRecombination) (400 mg/1 vial) 301
vials
D Bevacizumab (GeneticalRecombination) (100 mg/4 ml/1 vial)
878 vials
E Bevacizumab (GeneticalRecombination) (400 mg/16 ml/1
vial) 627 vials
F Paclitaxel (100 mg/1 vial)1,070 vials
G Palonosetron Hydrochloride(0.75 mg/5 vials/1 case) 387 cases
H Nivolumab (GeneticalRecombination) (100 mg/1 vial) 196
vials
I Nivolumab (GeneticalRecombination) (20 mg/1 vial) 316
vials
J Trastuzumab Emtansine(Genetical Recombination) (100 mg/1
vial) 152 vials
K Pegfilgrastim (GeneticalRecombination) (3.6 mg/1 vial) 250
vials
L Palivizumab (GeneticalRecombination) (100 mg/1 vial) 264
vials
M Ustekinumab (GeneticalRecombination) (45 mg/1 vial) 155
vials
N Goserelin Acetate (10.8 mg/1syringe) 642 syringes
O Eculizumab (GeneticalRecombination) (300 mg/1 vial) 156
vials
P Human fibrinogen Human thrombin
(9.5 cm×4.8 cm/1 sheet) 410 sheets
Q Temozolomide (100 mg/5capsule/1 case) 271 cases
R Pertuzumab (GeneticalRecombination) (420 mg/14 ml/1
vial) 128 vials
S Trastuzumab (GeneticalRecombination) (150 mg/1 vial) 949
vials
T Trastuzumab (GeneticalRecombination) 60 mg/1 vial) 1,366
vials
U Eribulin Mesilate (1 mg/1 vial)
509 vials
V Azacitidine (100 mg/1 vial) 488
vials
W Agalsidase Beta (GeneticalRecombination) (35 mg/1 vial) 52
vials
X Agalsidase Beta (GeneticalRecombination) 5 mg/1 vial) 294
vials
Y Micafungin Sodium (50 mg/10vials/1 case) 492 cases
Z fulvestrant (250 mg/2 vials/1case) 206 cases
AA Sugammadex Sodium (200 mg/10vials/1 case) 412 cases
AB Dexmedetomidine Hydrochloride(200 μg/5 vials/1 case) 1,000 cases
AC Bortezomib (3 mg/1 vial) 202vials
AD Pomalidomide (4 mg/7capsules/1 case) 150 cases
AE Alglucosidase Alfa (GeneticalRecombination) (50 mg/1 vial) 546
vials
AF Denosumab (GeneticalRecombina-
tion) (120 mg/1 vial) 612 vials
AG Rituximab (GeneticalRecombination) (500 mg/ml/1 vial)
314 vials
AH Agalsidase Alfa (GeneticalRecombination) (3.5 mg/1 vial) 120
vials
AI Ranibizumab (GeneticalRecombination) (10 mg/ml/1 vial)
212 vials
AJ Lenalidomide Hydrate (5 mg/40capsules/1 case) 125 cases
AK Infliximab (GeneticalRecombination) (100 mg/1 vial)
4,180 vials
(4) Delivery period : From 1April, 2017 through 31 March, 2018
(5) Delivery place : AsahikawaMedical University
(6) Qualifications forparticipating in the tendering
procedures : Suppliers eligible for
participating in the proposedtender are those who shall :
A not come under Article 4 and 5of the Regulation concerning the
Contract for Asahikawa MedicalUniversity Furthermore, minors,
Person under Conservatorship orPerson under Assistance that
obtained the consent necessary forconcluding a contract may be
applicable under cases of specialreasons within the said clause,
B have the Grade A, Grade B orGrade C qualification during fiscal
2017 in the Hokkaido area in sales
of product for participating intenders by Single qualification for
every ministry and agency,
C prove to have obtained thefirst-class license for selling
drugs in accordance with the Law on
Securing Quality, Efficacy andSafety of Products including
Pharmaceuticals and MedicalDevices,
D not be currently under asuspension of business order as
instructed by President, AsahikawaMedical University.
(7) Time limit of tender : 17 : 00
15 March, 2017
(8) Contact point for the notice :
Tetsuya Hashiba, ProcurementSection, Accounting Division,
Asahikawa Medical University,2-1-1-1 Midorigaokahigashi,
Asahikawa-shi, Hokkaido, 078-8510Japan, TEL 0166-69-3068